Form 4: Xeris Biopharma Director Exercises Options and Sells Shares
SEC Form 4 Filing
Director John Johnson exercised stock options and sold shares of Xeris Biopharma Holdings, Inc. on March 18, 2024.
Summary
- On March 18, 2024, John Johnson, a director of Xeris Biopharma Holdings, Inc., exercised stock options to purchase 215,600 shares of common stock at a price of $1.99 per share.
- Following the exercise of these options, Johnson sold 215,600 shares at $1.99 per share.
- After the transaction, Johnson directly owns 751,412 shares of Xeris Biopharma Holdings, Inc.
Sentiment
Score: 5
Explanation: This is a neutral report on insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as an indicator of management's confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 10/05/2021 | Options to purchase shares fully vested |
| 03/18/2024 | Director exercised stock options and sold shares |
| 11/14/2029 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.